Gemoscan Canada, Inc. ("Gemoscan" or the "Company") – (TSX-V:GES), (MUN:1GE) announces that, further to its press release of September 12, 2012, it is seeking approval from the TSX Venture Exchange ("TSXV") to extend an existing shares for service application (the "Original Submission"). Under the Original Submission, the Company issues shares for services to a consultant of the Company in exchange for the provision of certain strategic advisory services. The Company has applied to the TSXV to extend the Original Submission by a three month term (the "Extension Term"), with the Extension Term running consecutively from the Company's Original Submission.

Pursuant to the Extension Term, the Company will be issuing Cdn.$7,000 in Class A Shares ("Shares") per month to the consultant. The number of Shares to be issued to the consultant each month will be determined by using the closing price of the Shares on the TSXV on the first trading day of the month following the month for which the services were rendered by the consultant.

The provisions of the Extension Term are subject to approval by the TSXV and to compliance with all applicable regulatory requirements.

ABOUT GEMOSCAN CANADA, INC.

Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology; Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODETM Food Intolerance System, a personalized naturopathic nutritional program that promotes well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange (TSX-V) under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward-looking statements are subject to a number of significant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company website: www.gemoscan.com

CONTACT: FOR ADDITIONAL INFORMATION CONTACT:
         
         Gemoscan Canada, Inc.
         Brian Kalish
         Director, President and CEO
         (416) 650-1200
         Email: bkalish@hemocode.com